News ArticleNSE's Consolidated Profit After Tax Surges 23% YoY to ₹2,578 Crore in Q2FY27
Total income rises 9% to ₹4,554 crore on higher cash market and equity options volumes; operating EBITDA doubles with 76% margin
National Stock Exchange of India (NSE) posted a 23% year-on-year increase in consolidated profit after tax to ₹2,578 crore for Q2FY27, supported by a 9% rise in total income to ₹4,554 crore driven by higher volumes in cash markets and equity options. Operating EBITDA surged 107% to ₹3,079 crore with margin at 76%, while half-year consolidated net profit increased 13% to ₹5,698 crore. The exchange also contributed ₹41,234 crore to the exchequer in H1FY27.
National Stock Exchange of India Limited
General / Other
The National Stock Exchange of India reported a 23% year-on-year increase in consolidated profit after tax amounting to ₹2,578 crore for the second quarter of fiscal year 2027, driven by a 9% rise in total income to ₹4,554 crore primarily due to higher trading volumes in cash markets and equity options.
Consolidated revenue from transaction charges increased 9% to ₹3,035 crore, supported by a 24% year-on-year rise in average daily traded volume (ADTV) in the cash market segment to ₹1,18,377 crore, and a 3% increase in ADTV for equity options to ₹47,977 crore.
Other revenue streams also grew with data feed and terminal services revenue rising 43% to ₹165 crore, listing services revenue up 70% to ₹150 crore, and operating investment income increasing 9% to ₹237 crore, compared to the same quarter last year.
Total consolidated expenditure for the quarter decreased by 51% to ₹1,161 crore, partly due to a prior year provision of ₹1,297 crore related to SEBI settlement fees, resulting in operating EBITDA of ₹3,079 crore and a margin of 76%.
Earnings per share on a non-annualized basis rose to ₹10.41 from ₹8.48 year-on-year in Q2FY27. For the first half of FY27, consolidated total income was ₹9,807 crore, operating EBITDA ₹6,674 crore, and net profit ₹5,698 crore.
On a standalone basis, NSE's total income rose 8% to ₹3,956 crore, with operating EBITDA at ₹2,622 crore and a profit after tax of ₹2,164 crore for Q2FY27. Profit margins stood at 55% for the quarter and 56% for the first half year period.
Highlights
- Consolidated profit after tax for Q2FY27 increased by 23% YoY to ₹2,578 crore.
- Consolidated total income increased 9% YoY to ₹4,554 crore, driven by higher transaction charges from cash markets and equity options.
- Average daily traded volume in cash market rose 24% YoY to ₹1,18,377 crore in Q2FY27.
- Operating EBITDA jumped 107% YoY to ₹3,079 crore with a 76% margin in Q2FY27.
- NSE contributed ₹41,234 crore to the Indian exchequer in H1FY27, including ₹34,788 crore from securities transaction tax and commodity transaction tax.
- Standalone profit after tax grew 16% YoY to ₹2,164 crore with a 55% margin in Q2FY27.
Key Data Snapshot
What happened
- NSE reported a 23% increase in consolidated profit after tax to ₹2,578 crore for Q2FY27 compared to ₹2,098 crore in Q2FY26.
- Consolidated total income rose 9% year-on-year to ₹4,554 crore, driven primarily by higher transaction charges from increased market activity.
- Average daily traded volume (ADTV) in cash market surged by 24% to ₹1,18,377 crore in Q2FY27.
- Operating EBITDA doubled to ₹3,079 crore with a margin of 76%, benefiting from lower expenditure due to prior year provisions.
- Standalone profit after tax increased 16% year-on-year to ₹2,164 crore in Q2FY27 with a profit margin of 55%.
Key details
- Revenue from transaction charges increased by 9% to ₹3,035 crore in Q2FY27 from ₹2,789 crore in Q2FY26.
- Cash market trading had an ADTV of ₹1,18,377 crore, while equity options ADTV was ₹47,977 crore in Q2FY27.
- Data feed and terminal services income rose by 43% to ₹165 crore and listing services income increased 70% to ₹150 crore compared to Q2FY26.
- Consolidated total expenditure reduced by 51% to ₹1,161 crore in Q2FY27, due to absence of SEBI settlement fees provision present in prior year.
- During H1FY27, NSE's contribution to the exchequer totaled ₹41,234 crore, led by securities transaction tax and commodity transaction tax.
Regulatory and governance context
- NSE completed its listing on the stock exchange during Q2FY27, marking a significant milestone in the company's governance and transparency.
- The exchange facilitated India's first-ever tokenised bond issuances aggregating ₹1,000 crore during the quarter.
- NSE obtained regulatory approvals for new derivatives products including futures on the Nifty India FPI 150 Index and Corporate Bond Index Futures.
- The quarter marked 30 years of NSE Clearing's operations supporting India's capital markets.
Highlights
- Consolidated profit after tax for Q2FY27 increased by 23% YoY to ₹2,578 crore.
- Consolidated total income increased 9% YoY to ₹4,554 crore, driven by higher transaction charges from cash markets and equity options.
- Average daily traded volume in cash market rose 24% YoY to ₹1,18,377 crore in Q2FY27.
- Operating EBITDA jumped 107% YoY to ₹3,079 crore with a 76% margin in Q2FY27.
- NSE contributed ₹41,234 crore to the Indian exchequer in H1FY27, including ₹34,788 crore from securities transaction tax and commodity transaction tax.
- Standalone profit after tax grew 16% YoY to ₹2,164 crore with a 55% margin in Q2FY27.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Biocon Limited Reports Q2 FY2027 Profit of Rs. 917 Million and Announces New CTO Appointment
Biocon Limited disclosed its unaudited standalone financial results for the quarter and half year ending September 30, 2026, with a quarterly profit of Rs. 917 million. The board also approved the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as CTO starting January 1, 2027.
Read Full Story
Biocon Reports Q2 FY27 Total Income of Rs 4,423 Crore With Biopharma Revenue Up 5% and $400 Million Pertuzumab Deal
Biocon Limited announced consolidated total income of Rs 4,423 crore for the second quarter of fiscal year 2027, with biopharma revenues increasing by 5% year-on-year to Rs 3,583 crore. The company's EBITDA was reported at Rs 865 crore and net profit at Rs 41 crore. A significant highlight includes securing a 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at about USD 400 million.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 Million Revenue in Q2 FY27 with Net Profit at Rs. 9,255 Million
Zydus Lifesciences Limited reported strong revenue growth of 29% year-on-year in Q2 FY27 at Rs. 79,096 million, driven by its branded pharma businesses in India, North America, and international markets. However, net profit declined 27% to Rs. 9,255 million, and EBITDA dropped 6% to Rs. 18,945 million, reflecting cost and margin pressures.
Read Full Story
